Literature DB >> 12927756

Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus.

Le H Song1, Vu Q Binh, Dinh N Duy, Jürgen F J Kun, Thomas C Bock, Peter G Kremsner, Adrian J F Luty.   

Abstract

BACKGROUND/
OBJECTIVES: An ineffective cytokine response is thought to be one of the reasons for the failure to suppress hepatitis B virus (HBV) replication and to eliminate the virus. We investigated the serum levels of interleukin (IL)-6, IL-10, IL-12, and interferon (IFN)-gamma in HBV-infected Vietnamese patients to determine whether they were related to the outcome of HBV infection. STUDY
DESIGN: Samples from a total of 154 HBV-infected patients with well-characterised clinical profiles and 56 healthy controls were assessed.
RESULTS: Serum IL-6 levels, which were inversely correlated with transaminase levels, were highest in patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC) and lowest in those with either asymptomatic (ASYM), acute or chronic HBV, and thus, represented the best marker of HBV-related clinical progression. Compared with the healthy control group, serum IL-12 was uniformly elevated in all HBV-infected patients apart from those with ASYM infections, implying no impairment of production of this cytokine in HBV-infected individuals. Serum IL-10 and IFN-gamma levels, however, were uniformly low and showed no association with clinical presentation. Cytokine profiles were not influenced by the presence of hepatitis B e antigen (HbeAg).
CONCLUSIONS: Serum IL-6 and IL-12 but not IL-10 and IFN-gamma are associated with the clinical presentation in HBV-infected Vietnamese patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927756     DOI: 10.1016/s1386-6532(02)00271-8

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  24 in total

1.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 2.  Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Chiao-Fang Teng; Han-Chieh Wu; Woei-Cherng Shyu; Long-Bin Jeng; Ih-Jen Su
Journal:  Cell Transplant       Date:  2017-02-14       Impact factor: 4.064

3.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

4.  Circulating Biomarkers and their Possible Role in Pathogenesis of Chronic Hepatitis B and C Viral Infections.

Authors:  Saba Khan; Arpit Bhargava; Neelam Pathak; Kewal K Maudar; Subodh Varshney; Pradyumna K Mishra
Journal:  Indian J Clin Biochem       Date:  2011-01-05

Review 5.  Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.

Authors:  Xuefen Li; Xia Liu; Li Tian; Yu Chen
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

6.  HBV replication is significantly reduced by IL-6.

Authors:  Tzer-Min Kuo; Cheng-Po Hu; Ya-Ling Chen; Ming-Hsiang Hong; King-Song Jeng; Chun-Chin T Liang; Mong-Liang Chen; Chungming Chang
Journal:  J Biomed Sci       Date:  2009-04-20       Impact factor: 8.410

7.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Authors:  Christina M Martin; Jeffrey A Welge; Norah J Shire; Mohamed T Shata; Kenneth E Sherman; Jason T Blackard
Journal:  Cytokine       Date:  2009-07-21       Impact factor: 3.861

8.  Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.

Authors:  Holger G Hass; Thomas Bock; Oliver Nehls; Stephan Kaiser
Journal:  J Gastroenterol       Date:  2009-05-21       Impact factor: 7.527

9.  Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.

Authors:  Tao Chen; Shen-Jun Yuan; Jing Wang; Wei Hu
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

10.  IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India.

Authors:  Roli Saxena; Yogesh Kumar Chawla; Indu Verma; Jyotdeep Kaur
Journal:  Mol Cell Biochem       Date:  2013-10-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.